REFRACTORY LYMPHOMA
Clinical trials for REFRACTORY LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The trial includes up to 49 participants,…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
Triple-Drug attack shows promise against tough blood cancer
Disease control Recruiting nowThis study tests a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma that has come back or not responded to treatment, as well as for those who haven't been treated yet. The goal is to find the best dose and see how many…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Austin I Kim • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
Engineered immune cells take on hard-to-treat lymphoma in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 17, 2026 00:28 UTC
-
New drug cocktail aims to beat back lymphoma in relapsed patients
Disease control Recruiting nowThis study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for kids with relapsed cancers: experimental drug CBL0137 enters trials
Disease control Recruiting nowThis study tests an experimental drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors by …
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Vitamin c boost: could high doses help chemo fight tough lymphomas?
Disease control Recruiting nowThis phase 2 trial tests whether adding high-dose vitamin C to standard chemotherapy can improve outcomes for people with lymphoma that has returned or not responded to treatment, as well as for those with related blood disorders like chronic myelomonocytic leukemia. About 80 adu…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New CAR-T therapy targets stubborn leukemia and lymphoma
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to attack ca…
Matched conditions: REFRACTORY LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 06, 2026 16:02 UTC